Core Viewpoint - BGM Group Ltd. has received a notification from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 20-F for the fiscal year ended September 30, 2025 [1][2]. Compliance and Regulatory Actions - The company has 60 calendar days to submit a plan to Nasdaq to regain compliance, with a potential extension of up to 180 days if the plan is accepted [2]. - If the plan is not accepted, the company can appeal the decision to a Hearing Panel, but the notification does not immediately affect the listing of its class A ordinary shares [3]. Company Operations and Focus - BGM Group Ltd. focuses on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [5]. - In AI applications, the company utilizes advanced analytics and AI Agent technology to provide solutions for insurance companies, covering areas such as sales, underwriting, claims processing, and customer service [6]. - The biopharmaceutical division produces oxytetracycline API, crude heparin sodium, and licorice preparations, integrating AI-assisted decision-making to optimize supply chains and improve process efficiency [7].